Overview

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Status:
Not yet recruiting
Trial end date:
2024-05-29
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the number of baseline IFN-γ SFUs to the number of IFN-γ SFUs after a 6-day oral gluten challenge among participants treated with TAK-101 versus placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda